Citation
Chen, Kaiyan, et al. "Prognostic Significance of Programmed Death-1 and Programmed Death-ligand 1 Expression in Patients With Esophageal Squamous Cell Carcinoma." Oncotarget, vol. 7, no. 21, 2016, pp. 30772-80.
Chen K, Cheng G, Zhang F, et al. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2016;7(21):30772-80.
Chen, K., Cheng, G., Zhang, F., Zhang, N., Li, D., Jin, J., Wu, J., Ying, L., Mao, W., & Su, D. (2016). Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget, 7(21), 30772-80. https://doi.org/10.18632/oncotarget.8956
Chen K, et al. Prognostic Significance of Programmed Death-1 and Programmed Death-ligand 1 Expression in Patients With Esophageal Squamous Cell Carcinoma. Oncotarget. 2016 May 24;7(21):30772-80. PubMed PMID: 27120796.
TY - JOUR
T1 - Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
AU - Chen,Kaiyan,
AU - Cheng,Guoping,
AU - Zhang,Fanrong,
AU - Zhang,Nan,
AU - Li,Dan,
AU - Jin,Jiaoyue,
AU - Wu,Junzhou,
AU - Ying,Lisha,
AU - Mao,Weimin,
AU - Su,Dan,
PY - 2016/02/14/received
PY - 2016/04/02/accepted
PY - 2016/4/28/entrez
PY - 2016/4/28/pubmed
PY - 2017/12/30/medline
KW - PD-1
KW - PD-L1
KW - esophageal cancer
KW - immunochemistry
KW - prognosis
SP - 30772
EP - 80
JF - Oncotarget
JO - Oncotarget
VL - 7
IS - 21
N2 - AIMS: To evaluate the expression of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) and their clinical and prognostic significance in primary esophageal squamous cell carcinoma (ESCC). RESULTS: The expression rate of PD-1 and PD-L1 in ESCC was 33.5% (117/349) and 41.4% (222/536), respectively. PD-L1 expression differed significantly by tumor location, grade, lymph node metastases, and disease stage (P < 0.05). Moreover, its expression was associated with the disease free survival (DFS). Patients with positive PD-L1 expression had reduced risk for disease relapse compared to those without PD-L1 expression (Hazard ratio [HR] = 0.75, 95% confidence interval [CI]: 0.56-1.00, P = 0.048). Kaplan-Meier curves showed the similar result, P = 0.047. However, there was no significant correlation between PD-1 expression and clinicopathological factors or outcome in ESCC (P > 0.05). METHODS: The expression of PD-1 and PD-L1 was assessed by immunohistochemistry on tissue microarrays from 536 primary ESCC who underwent surgery during January 2008 and April 2012 in Zhejiang Cancer Hospital. Chi-square test and Cox proportional hazards regression were employed to analyze the associations between their expressions and clinicopathological variables and survival. CONCLUSIONS: Our results suggested that PD-L1 could be a favorable indicator of prognosis in ESCC.
SN - 1949-2553
UR - https://www.unboundmedicine.com/medline/citation/27120796/Prognostic_significance_of_programmed_death_1_and_programmed_death_ligand_1_expression_in_patients_with_esophageal_squamous_cell_carcinoma_
L2 - http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=8956
DB - PRIME
DP - Unbound Medicine
ER -